Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1,845.86% | 318.22% | 84.39% | 39.07% | -47.39% |
| Total Depreciation and Amortization | 106.14% | 109.25% | 107.09% | 12.04% | 3.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.28% | 40.53% | 8.82% | 62.30% | -63.03% |
| Change in Net Operating Assets | 75.13% | 173.93% | -116.41% | -134.53% | 68.25% |
| Cash from Operations | 332.42% | 1,695.22% | -94.91% | -23.05% | 71.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -34.55% | 18.18% | -- | -- | -68.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -56.93% | 417.62% | 267.98% | -51.85% | -138.12% |
| Cash from Investing | -58.77% | 424.96% | 267.98% | -59.72% | -136.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 201.44% | 1,655.56% | -54.43% | 8,800.00% | -16.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1,038.95% | -8.42% | -214.13% | 100.00% |
| Cash from Financing | 201.44% | -1,032.57% | -101.61% | -113.14% | 123.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.02% | 560.24% | 22.89% | -145.57% | -133.55% |